BD (Becton, Dickinson and Company) announced a strategic collaboration with Ypsomed on October 23, 2024, to advance self-injection solutions for high-viscosity biologic drugs. This partnership aims to address current limitations in delivering these complex therapies.
The collaboration involves streamlining the integration of BD Neopak™ XtraFlow™ Glass Prefillable Syringe with Ypsomed's YpsoMate® 2.25 autoinjector platform. This combined solution is designed to enable the delivery of biologic drugs with viscosities greater than 15cP in an autoinjector format.
The BD Neopak™ XtraFlow™ syringe features a shorter, 8-millimeter needle length and thinner wall cannula to optimize subcutaneous delivery, enhancing flow and usability. This initiative supports pharmaceutical partners in de-risking and accelerating combination product development, bringing life-saving therapies to patients faster.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.